Cytiva, now with the life sciences business from Pall Corporation, is a global biotechnology leader dedicated to helping customers discover and commercialize the next generation of therapeutics. We bring dedicated technical expertise and a broad portfolio of tools, technologies, and services that enable the development, manufacture, and delivery of transformative medicines to patients. We're the provider of leading life science brands such as ÄKTA, Amersham, HyClone, MabSelect and Whatman. We are part of Danaher, a global science and technology leader. Along with other Danaher businesses, we accelerate the impact of tomorrow’s science and technology innovation to improve human health. Visit https://www.cytiva.com/privacy to review our privacy policy.
Unlock the market timeline & signal feed
352 signals in the last 90 days.
The order this company entered each market — oldest to newest
Commercial Compliance
Project Engineer (Product quality control)
Sign up to see the full signal feed
How Cytiva's international expansion compares to its competitors
CytivaYouBars show relative size across the companies compared.
5 metrics| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 CytivaYou | 26 | 0 | -23% | 339 | 37 |
Scaling fast — 300 roles opened in the last 90 days, up 200% vs the prior period. Engineering-led and concentrated in France.
WP. Kuala Lumpur, Federal Territory of Kuala Lumpur, Malaysia · yesterday
Commercial Compliance
Pune/Pimpri-Chinchwad Area · yesterday
Project Engineer (Product quality control)
Pune/Pimpri-Chinchwad Area · 2d ago
Electrical Engineer II
49 technologies detected across the stack.
71 active campaigns across 131 markets.
Active3 mentions in the last 90 days.
Danaher held its 2026 Life Sciences Innovation Summit in Shenzhen, announcing strategic partnerships with research institutions and Chinese companies to advance AI-driven drug discovery, spatial proteomics, and intelligent laboratory development.
Global oligonucleotide synthesizer market projected to grow from $232M in 2025 to $435M by 2032, driven by nucleic acid drug development and molecular diagnostics demand.
Saviynt surpassed $300M in annual recurring revenue with 80% bookings growth and launched Zuma, an AI identity security platform managing AI agents and non-human identities.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Cytiva's business, markets, and growth signals.
“We reach accounts the week they land in-market — not the quarter after.”
Book a walkthrough of the movement map with our team.
Pubrio turns expansion signals across 200+ markets into one live graph, so revenue teams see which companies are entering new markets, and act on the timing.
© 2026 Pubrio. All rights reserved.
